David Onions was recently promoted from the role of chief scientific officer of Invitrogen unit BioReliance to chief medical officer of Invitrogen. The position is a new one at Invitrogen and a seemingly unusual role for someone at a firm focused on developing and selling molecular biology tools. This week, Onions spoke with BioCommerce Week about his new position and Invitrogen's strategy for more collaborative efforts in medical research that are closer to the patient.

Why does Invitrogen need a chief medical officer?

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.